by Carrie Strehlau
Highly sensitive genomic analysis of acute lymphoblastic leukemia cells reveals for the first time how the malignant cells evolve to cause relapse.
By genomic sequencing of leukemia cells from relapsed patients at different stages, scientists have discovered key details of how acute lymphoblastic leukemia (ALL) cells mutate to survive chemotherapy. These mutations enable the cells to proliferate, causing relapse and often death.
The findings are important because ALL is a leading cause of cancer deaths in children, with 15 percent of ALL patients relapsing with poor survival. The researchers said their findings will lead to new tests to monitor children in remission and to detect signs of relapse.
The research was published in the March 19 issue of the journal Nature Communications. Leading the research team were corresponding authors Charles Mullighan, M.D., MBBS(Hons), a member of the St. Jude Children's Research Hospital Department of Pathology; Jinghui Zhang, Ph.D., a member of the St. Jude Department of Computational Biology; and Stephen Hunger, M.D., director of the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia.
In their study, the researchers analyzed the genomes of cells from 20 children who had ALL that returned following treatment. Importantly, the researchers analyzed cell samples taken at three stages—diagnosis, remission and relapse.
Thus, the scientists could analyze in detail the genomes of the cells at the different stages, determining the mutations that drove the relapse of leukemia. Cancers such as leukemia are not a homogeneous disease. Rather they are a witch's brew of different dividing cancer cells, called "clones," with distinctive sets of mutations. While chemotherapy might kill almost all the clones, some might have escaped therapy, leaving them to multiply to cause relapse.
"In our study we wanted to find out the underlying mechanism leading to cancer relapse," Zhang said. "When the cancer recurs, is it a completely different cancer, or is it an extension, or change, arising from pre-existing cancer?"
New genomic analytical technologies enabled the scientists to detect with great sensitivity the mutations in both the "rising" and "falling" clones at the different stages. Previous studies have attempted to work backward by genomically analyzing the relapsed clone to try to trace back its origin. However, such analysis would miss the low levels of the cells that, at diagnosis, would ultimately cause relapse.
The researchers' genomic analysis of the cancer clonal cells pinpointed the mutations that drove the leukemia. They also characterized how diverse those mutations were at both diagnosis and relapse—finding that the cancer cells were mutating just as wildly and diversely throughout the cancer process.
"This finding was interesting, because most people think that the clone that has the most mutations is more likely to survive therapy and evolve, but that doesn't seem to be the case," Zhang said.
A key finding was that in most cases relapse of the cancer was driven by a minor clone, or "subclone," present at an extremely low level, that survived therapy. This finding has implications for genomic analysis of ALL after a patient's treatment, to determine the likelihood of relapse.
"When we are analyzing for the level of minimum residual disease in monitoring remission in patients, we should not only pay attention to the mutations in the predominant clone," said Zhang. "We should also be tracking what kinds of mutations exist in the minor subclones."
In their analysis, the researchers identified seven specific genes that were highly likely to be mutated in relapsed disease. Researchers at St. Jude and elsewhere are currently exploring the biological functions of the relapse-related genes, and the results may aid in developing ways to identify drugs to target their function.
More broadly, the methodology of highly sensitive genomic analysis of cancer cells that Zhang and her colleagues developed can be applied to explore the evolution of other cancers.
Explore further: Chromosomal rearrangement is the key to progress against aggressive infant leukemia
Medical Xpress on facebook
Related Stories
Chromosomal rearrangement is the key to progress against aggressive infant leukemia
Mar 06, 2015
The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project reports that a highly aggressive form of leukemia in infants has surprisingly few mutations beyond the chromosomal ...
Tracking down the origin of leukemia relapse
Apr 04, 2011
The cancer cells that reign during relapses of an aggressive human leukemia are different from those that dominated the original disease, according to a paper published online on April 4 in the Journal of Experimental Me ...
Common mutation is culprit in acute leukemia relapse
Mar 06, 2014
Harvard stem cell scientists have identified a mutation in human cases of acute lymphoblastic leukemia that likely drives relapse. The research, published in Cancer Cell, could translate into improved patien ...
Chemotherapy may influence leukemia relapse: research
Jan 11, 2012
The chemotherapy drugs required to push a common form of adult leukemia into remission may contribute to DNA damage that can lead to a relapse of the disease in some patients, findings of a new study suggest.
Researchers reveal genomic diversity of individual lung tumors
Oct 09, 2014
Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper ...
Recommended for you
Text message reminders boost breast cancer screening attendance
2 minutes ago
Women who received a text message reminding them about their breast cancer screening appointment were 20 per cent more likely to attend than those who were not texted, according to a study published in the British Journal of ...
Breast implants could become safer thanks to cell-friendly surface
2 hours ago
Scientists at The University of Manchester have created an enhanced surface for silicone breast implants which could reduce complications and make them less likely to be rejected by the body.
Targeted drug doubles progression free survival in Hodgkin lymphoma
13 hours ago
A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without ...
C-reactive protein independent prognostic marker in melanoma
16 hours ago
(HealthDay)—C-reactive protein (CRP) levels are an independent prognostic marker in melanoma, according to a study published online March 16 in the Journal of Clinical Oncology.
Doctors say women with aytpia or DCIS should seek second opinions after breast biopsies
17 hours ago
While doctors almost always agree on a pathological diagnosis of invasive breast cancer, there is room for improvement when diagnosing atypia (or atypical ductal hyperplasia-ADH) and DCIS (ductal carcinoma in-situ), Anna ...
mHealth app ideal for breast cancer risk assessment, prevention
17 hours ago
Interviewing women at a breast-imaging center in an urban safety net institution before and after they used a "mHealth" mobile health app on a tablet, Elissa Ozanne, PhD from Dartmouth's Norris Cotton Cancer Center and colleagues ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
by Carrie Strehlau
Highly sensitive genomic analysis of acute lymphoblastic leukemia cells reveals for the first time how the malignant cells evolve to cause relapse.
By genomic sequencing of leukemia cells from relapsed patients at different stages, scientists have discovered key details of how acute lymphoblastic leukemia (ALL) cells mutate to survive chemotherapy. These mutations enable the cells to proliferate, causing relapse and often death.
The findings are important because ALL is a leading cause of cancer deaths in children, with 15 percent of ALL patients relapsing with poor survival. The researchers said their findings will lead to new tests to monitor children in remission and to detect signs of relapse.
The research was published in the March 19 issue of the journal Nature Communications. Leading the research team were corresponding authors Charles Mullighan, M.D., MBBS(Hons), a member of the St. Jude Children's Research Hospital Department of Pathology; Jinghui Zhang, Ph.D., a member of the St. Jude Department of Computational Biology; and Stephen Hunger, M.D., director of the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia.
In their study, the researchers analyzed the genomes of cells from 20 children who had ALL that returned following treatment. Importantly, the researchers analyzed cell samples taken at three stages—diagnosis, remission and relapse.
Thus, the scientists could analyze in detail the genomes of the cells at the different stages, determining the mutations that drove the relapse of leukemia. Cancers such as leukemia are not a homogeneous disease. Rather they are a witch's brew of different dividing cancer cells, called "clones," with distinctive sets of mutations. While chemotherapy might kill almost all the clones, some might have escaped therapy, leaving them to multiply to cause relapse.
"In our study we wanted to find out the underlying mechanism leading to cancer relapse," Zhang said. "When the cancer recurs, is it a completely different cancer, or is it an extension, or change, arising from pre-existing cancer?"
New genomic analytical technologies enabled the scientists to detect with great sensitivity the mutations in both the "rising" and "falling" clones at the different stages. Previous studies have attempted to work backward by genomically analyzing the relapsed clone to try to trace back its origin. However, such analysis would miss the low levels of the cells that, at diagnosis, would ultimately cause relapse.
The researchers' genomic analysis of the cancer clonal cells pinpointed the mutations that drove the leukemia. They also characterized how diverse those mutations were at both diagnosis and relapse—finding that the cancer cells were mutating just as wildly and diversely throughout the cancer process.
"This finding was interesting, because most people think that the clone that has the most mutations is more likely to survive therapy and evolve, but that doesn't seem to be the case," Zhang said.
A key finding was that in most cases relapse of the cancer was driven by a minor clone, or "subclone," present at an extremely low level, that survived therapy. This finding has implications for genomic analysis of ALL after a patient's treatment, to determine the likelihood of relapse.
"When we are analyzing for the level of minimum residual disease in monitoring remission in patients, we should not only pay attention to the mutations in the predominant clone," said Zhang. "We should also be tracking what kinds of mutations exist in the minor subclones."
In their analysis, the researchers identified seven specific genes that were highly likely to be mutated in relapsed disease. Researchers at St. Jude and elsewhere are currently exploring the biological functions of the relapse-related genes, and the results may aid in developing ways to identify drugs to target their function.
More broadly, the methodology of highly sensitive genomic analysis of cancer cells that Zhang and her colleagues developed can be applied to explore the evolution of other cancers.
Explore further: Chromosomal rearrangement is the key to progress against aggressive infant leukemia
Medical Xpress on facebook
Related Stories
Chromosomal rearrangement is the key to progress against aggressive infant leukemia
Mar 06, 2015
The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project reports that a highly aggressive form of leukemia in infants has surprisingly few mutations beyond the chromosomal ...
Tracking down the origin of leukemia relapse
Apr 04, 2011
The cancer cells that reign during relapses of an aggressive human leukemia are different from those that dominated the original disease, according to a paper published online on April 4 in the Journal of Experimental Me ...
Common mutation is culprit in acute leukemia relapse
Mar 06, 2014
Harvard stem cell scientists have identified a mutation in human cases of acute lymphoblastic leukemia that likely drives relapse. The research, published in Cancer Cell, could translate into improved patien ...
Chemotherapy may influence leukemia relapse: research
Jan 11, 2012
The chemotherapy drugs required to push a common form of adult leukemia into remission may contribute to DNA damage that can lead to a relapse of the disease in some patients, findings of a new study suggest.
Researchers reveal genomic diversity of individual lung tumors
Oct 09, 2014
Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper ...
Recommended for you
Text message reminders boost breast cancer screening attendance
2 minutes ago
Women who received a text message reminding them about their breast cancer screening appointment were 20 per cent more likely to attend than those who were not texted, according to a study published in the British Journal of ...
Breast implants could become safer thanks to cell-friendly surface
2 hours ago
Scientists at The University of Manchester have created an enhanced surface for silicone breast implants which could reduce complications and make them less likely to be rejected by the body.
Targeted drug doubles progression free survival in Hodgkin lymphoma
13 hours ago
A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without ...
C-reactive protein independent prognostic marker in melanoma
16 hours ago
(HealthDay)—C-reactive protein (CRP) levels are an independent prognostic marker in melanoma, according to a study published online March 16 in the Journal of Clinical Oncology.
Doctors say women with aytpia or DCIS should seek second opinions after breast biopsies
17 hours ago
While doctors almost always agree on a pathological diagnosis of invasive breast cancer, there is room for improvement when diagnosing atypia (or atypical ductal hyperplasia-ADH) and DCIS (ductal carcinoma in-situ), Anna ...
mHealth app ideal for breast cancer risk assessment, prevention
17 hours ago
Interviewing women at a breast-imaging center in an urban safety net institution before and after they used a "mHealth" mobile health app on a tablet, Elissa Ozanne, PhD from Dartmouth's Norris Cotton Cancer Center and colleagues ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment